20,000 Shares in Progyny, Inc. (NASDAQ:PGNY) Bought by Quinn Opportunity Partners LLC

Quinn Opportunity Partners LLC purchased a new position in shares of Progyny, Inc. (NASDAQ:PGNY - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor purchased 20,000 shares of the company's stock, valued at approximately $345,000.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Vanguard Group Inc. grew its stake in Progyny by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 8,692,132 shares of the company's stock worth $149,939,000 after buying an additional 48,271 shares during the last quarter. Pacer Advisors Inc. grew its stake in shares of Progyny by 47.5% during the fourth quarter. Pacer Advisors Inc. now owns 3,676,200 shares of the company's stock worth $63,414,000 after acquiring an additional 1,183,558 shares during the last quarter. State Street Corp increased its holdings in shares of Progyny by 4.5% during the third quarter. State Street Corp now owns 3,113,654 shares of the company's stock valued at $52,185,000 after acquiring an additional 134,861 shares in the last quarter. River Road Asset Management LLC purchased a new position in shares of Progyny in the 4th quarter valued at approximately $25,529,000. Finally, Fort Washington Investment Advisors Inc. OH boosted its stake in Progyny by 90.1% in the 4th quarter. Fort Washington Investment Advisors Inc. OH now owns 1,467,780 shares of the company's stock worth $25,319,000 after purchasing an additional 695,740 shares in the last quarter. Hedge funds and other institutional investors own 94.93% of the company's stock.

Progyny Stock Performance

NASDAQ PGNY traded down $0.27 during mid-day trading on Tuesday, reaching $21.81. 1,077,203 shares of the stock were exchanged, compared to its average volume of 1,733,621. The company has a market capitalization of $1.86 billion, a P/E ratio of 37.60, a P/E/G ratio of 2.39 and a beta of 1.33. The business's 50 day moving average is $21.99 and its 200-day moving average is $18.74. Progyny, Inc. has a 1 year low of $13.39 and a 1 year high of $33.85.

Remove Ads

Wall Street Analyst Weigh In

A number of research analysts have issued reports on PGNY shares. Bank of America upped their price target on shares of Progyny from $21.00 to $25.00 and gave the company a "buy" rating in a research note on Tuesday, February 11th. BTIG Research upgraded Progyny from a "neutral" rating to a "buy" rating and set a $28.00 target price for the company in a research note on Monday, March 31st. JPMorgan Chase & Co. boosted their price target on Progyny from $17.00 to $23.00 and gave the company a "neutral" rating in a research note on Tuesday, January 28th. Finally, Canaccord Genuity Group lifted their target price on Progyny from $17.00 to $23.00 and gave the stock a "hold" rating in a report on Friday, February 28th. Eight research analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to MarketBeat, Progyny currently has an average rating of "Hold" and a consensus target price of $23.64.

About Progyny

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.